The farnesoid X receptor (FXR) is expressed predominantly in tissues exposed to high levels of bile acids and controls bile acid and lipid homeostasis. FXR？/？ mice develop hepatocellular carcinoma (HCC) and show an increased prevalence for intestinal malignancies, suggesting a role of FXR as a tumor suppressor in enterohepatic tissues. The N-myc downstream-regulated gene 2 (NDRG2) has been recognized as a tumor suppressor gene, which is downregulated in human hepatocellular carcinoma, colorectal carcinoma and many other malignancies. We show reduced NDRG2 mRNA in livers of FXR？/？ mice compared to wild type mice and both, FXR and NDRG2 mRNAs, are reduced in human HCC compared to normal liver. Gene reporter assays and Chromatin Immunoprecipitation data support that FXR directly controls NDRG2 transcription via IR1-type element(s) identified in the first introns of the human, mouse and rat NDRG2 genes. NDRG2 mRNA was induced by non-steroidal FXR agonists in livers of mice and the magnitude of induction of NDRG2 mRNA in three different human hepatoma cell lines was increased when ectopically expressing human FXR. Growth and metastasis of SK-Hep-1 cells was strongly reduced by non-steroidal FXR agonists in an orthotopic liver xenograft tumor model. Ectopic expression of FXR in SK-Hep1 cells reduced tumor growth and metastasis potential of corresponding cells and increased the anti-tumor efficacy of FXR agonists, which may be partly mediated via increased NDRG2 expression. FXR agonists may show a potential in the prevention and/or treatment of human hepatocellular carcinoma, a devastating malignancy with increasing prevalence and limited therapeutic options.
References
[1]
Higashiyama H, Kinoshita M, Asano S (2008) Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray. Acta Histochem 110: 86–93.
[2]
Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ (2006) Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126: 789–99.
[3]
Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6: 517–26.
[4]
Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, et al. (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6: 507–15.
[5]
Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365–8.
[6]
Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, et al. (1999) Identification of a nuclear receptor for bile acids. Science 284: 1362–5.
[7]
Huang WD, Ma K, Zhang J, Qatanani M, Cuvillier J, et al. (2006) Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312: 233–6.
[8]
Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, et al. (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. Med Chem 43: 2971–74.
[9]
Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, et al. (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281: 11039–49.
[10]
Zhang Y, Lee FY, Barrera G, Lee H, Vales C, et al. (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 10: 1006–11.
[11]
Ma K, Saha PK, Chan L, Moore DD (2006) Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116: 1102–9.
[12]
Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, et al. (2005) A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 314: 584–95.
[13]
Zhang S, Wang J, Liu Q, Harnish DC, Farnesoid X (2009) Receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 51: 380–8.
[14]
Wang Y-D, Chen W-D, Moore DD, Huang W (2008) FXR, a metabolic regulator and cell protector. Cell Research 18: 1087–95.
[15]
Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W (2007) Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 67: 863–7.
[16]
Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ (2007) Spontaneous hepatocellular carcinoma in farnesoid X receptor-null mice. Carcinogenesis 28: 940–6.
[17]
Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A (2008) Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res 68: 9589–94.
[18]
Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, et al. (2009) Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 328: 469–77.
[19]
Smith DL, Keshavan P, Avissar U, Ahmed K, Zucker SD (2010) Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor. Carcinogenesis 31: 1100–9.
[20]
De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, et al. (2004) The Bile Acid Nuclear Receptor FXR and the Bile Acid Binding Protein IBABP Are Differently Expressed in Colon Cancer. Dig Dis Sci 49: 982–9.
[21]
Lax S, Schauer G, Prein K, Kapitan M, Silbert D, et al. (2012) Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to non-neoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer 130: 2232–9.
[22]
Thomas AM, Hart SN, Kong B, Fang J, Zhong XB, et al. (2010) Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 51: 1410–9.
[23]
Chong HK, Infante AM, Seo YK, Jeon TI, Zhang Y, et al. (2010) Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1. Nucleic Acids Res 38: 6007–17.
[24]
Zhang Y, Xu P, Park K, Choi Y, Moore DD, et al. (2008) Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 48: 289–98.
[25]
He N, Park K, Zhang Y, Huang J, Lu S, et al. (2008) Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology 134: 793–802.
[26]
Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, et al. (2008) Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 68: 4210–20.
[27]
Lorentzen A, Vogel LK, Lewinsky RH, Saeb？ M, Skjelbred CF, et al. (2007) Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer 7: 192–8.
[28]
Kim YJ, Yoon SY, Kim JT, Song EY, Lee HG, et al. (2009) NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis 30: 598–605.
[29]
Piepoli A, Cotugno R, Merla G, Gentile A, Augello B, et al. (2009) Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics 2: 11–22.
[30]
Chu D, Zhang Z, Li Y, Wu L, Zhang J, et al. (2011) Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2. Mol Cancer Ther 10: 47–56.
[31]
Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, et al. (2008) Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 123: 2080–6.
[32]
Zhao H, Zhang J, Lu J, He X, Chen C, et al. (2008) Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer 8: 303–11.
[33]
Shi H, Li N, Li S, Chen C, Wang W, et al. (2010) Expression of NDRG2 in esophageal squamous cell carcinoma. Cancer Sci 101: 1292–9.
[34]
Ma J, Jin H, Wang H, Yuan J, Bao T, et al. (2008) Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull 31: 1316–20.
[35]
Song SP, Zhang SB, Liu R, Yao L, Hao YQ, et al. (2011) NDRG2 down-regulation and CD24 up-regulation promote tumor aggravation and poor survival in patients with gallbladder carcinoma. Med Oncol Dec 2. [Epub ahead of print].
[36]
Zheng J, Liu Q, Li Y, Yang J, Ma J, et al. (2010) NDRG2 Expression Regulates CD24 and Metastatic Potential of Breast Cancer Cells. Asian Pac J Cancer Prev 11: 1817–21.
[37]
Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, et al. (2000) Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 275: 10638–47.
[38]
Thomas AM, Hart SN, Kong B, Fang J, Zhong XB, et al. (2010) Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 51: 1410–9.
[39]
Chong HK, Infante AM, Seo YK, Jeon TI, Zhang Y, et al. (2010) Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1. Nucleic Acids Res 38: 6007–17.
[40]
Abel U, Schlüter T, Schulz A, Hambruch E, Steeneck C, et al. (2010) Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorg Med Chem Lett 20: 4911–7.
[41]
Boergesen M, Pedersen TA, Gross B, van Heeringen SJ, Hagenbeek D, et al. (2012) Genome-wide profiling of LXR, RXR and PPARα in mouse liver reveals extensive sharing of binding sites. Mol Cell Biol 32: 852–67.
[42]
Guo XZ, Friess H, Di Mola FF, Heinicke JM, Abou-Shady M, et al. (1998) KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma. Hepatology 28: 1481–8.
[43]
Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, et al. (2010) Combined Functional Genome Survey of Therapeutic Targets for Hepatocellular Carcinoma. Clin Cancer Res 16: 2518–28.
[44]
Shouval D, Schuger L, Levij I, Reid L, Neeman Z, et al. (1988) Comparative morphology and tumorigenicity of human hepatocellular carcinoma cell lines in athymic rats and mice. Virchows Archiv A Pathol Anat Histopathol 412: 595–606.
[45]
Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, et al. (2011) Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther 338: 12–21.
[46]
Dai J, Wang H, Shi Y, Dong Y, Zhang Y, et al. (2011) Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J Hematol Oncol 4: 41.
[47]
Zhong XY, Yu JH, Zhang WG, Wang ZD, Dong Q, et al. (2012) MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene 493: 44–51.
[48]
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378–90.
[49]
Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, et al. (2011) Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 21: 401–16.
[50]
Thompson MD, Monga SP (2007) WNT/beta-catenin signaling in liver health and disease. Hepatology 45: 1298–1305.
[51]
Liu N, Meng Z, Lou G, Zhou W, Wang X, et al. (2012) Hepatocarcinogenesis in FXR？/？ Mice Mimics Human HCC Progression That Operates through HNF1α Regulation of FXR Expression. Mol Endocrinol 26: 775–85.
[52]
Martinez-Becerra P, Vaquero J, Romero MR, Lozano E, Anadon C, et al. (2012) No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol Pharm 9: 1693–704.
[53]
Kremoser C, Abel U, Steeneck C, Kinzel O (2011) Patent Application WO2011/020615 Novel FXR (NR1H4) binding and activity modulating compounds.
